Suvi Kuivanen

Dr. Suvi Kuivanen


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2020 in Science
Verified
Journal Article
Open access
PDF file
LCLudovico Cantuti-Castelvetri
Ludovico Cantuti-Castelvetri
RORavi Ojha
Ravi Ojha
LPLiliana D. Pedro
Liliana D. Pedro
MDMinou Djannatian
Minou Djannatian
JFJonas Franz
Jonas Franz
MSMikael Simons
Mikael Simons
Another host factor for SARS-CoV-2: Virus-host interactions determine cellular entry and spreading in tissues. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the earlier SARS-CoV use angiotensin-converting enzyme 2 (ACE2) as a receptor; however, their tissue tropism differs, raising the possibility that additional host factors are involved. The spike protein of SARS-CoV-2 contains a cleavage site for the protease furin that is absent from SARS-CoV (see the Perspective by Kielian). Cantuti-Castelvetri et al. now show that neuropilin-1 (NRP1), which is known to bind furin-cleaved substrates, potentiates SARS-CoV-2 infectivity. NRP1 is abundantly expressed in the respiratory and olfactory epithelium, with highest expression in endothelial and epithelial cells. Daly et al. found that the furin-cleaved S1 fragment of the spike protein binds directly to cell surface NRP1 and blocking this interaction with a small-molecule inhibitor or monoclonal antibodies reduced viral infection in cell culture. Understanding the role of NRP1 in SARS-CoV-2 infection may suggest potential targets for future antiviral therapeutics. Science , this issue p. 856 , p. 861 ; see also p. 765

1 August 2020 in Journal of Clinical Virology
Verified
Journal Article
Closed access
AJAj Jääskeläinen
Aj Jääskeläinen
SKSuvi Kuivanen
Suvi Kuivanen
EKE Kekäläinen
E Kekäläinen
MAMj Ahava
Mj Ahava
RLR Loginov
R Loginov
MLM Lappalainen
M Lappalainen

4 July 2019 in Eurosurveillance
Verified
Journal Article
Open access
SKSuvi Kuivanen
Suvi Kuivanen
LLLev Levanov
Lev Levanov
LKLauri Kareinen
Lauri Kareinen
Tarja SironenTarja Sironen
Tarja Sironen
AJAnne J. Jääskeläinen
Anne J. Jääskeläinen
OVOlli Vapalahti
Olli Vapalahti
The newly identified tick-borne Alongshan virus (ALSV), a segmented Jingmen virus group flavivirus, was recently associated with human disease in China. We report the detection of ALSV RNA in Ixodes ricinus ticks in south-eastern Finland. Screening of sera from patients suspected for tick-borne encephalitis for Jingmen tick virus-like virus RNA and antibodies revealed no human cases. The presence of ALSV in common European ticks warrants further investigations on its role as a human pathogen.

24 June 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
MKMichael Kunze
Michael Kunze
Pavle BanovicPavle Banovic
Pavle Banovic
PBPetra Bogovič
Petra Bogovič
VBVioleta Tincuta Briciu
Violeta Tincuta Briciu
Rok ČivljakRok Čivljak
Rok Čivljak
WEWilhelm Erber
Wilhelm Erber
There has been an increase in reported TBE cases in Europe since 2015, reaching a peak in some countries in 2020, highlighting the need for better management of TBE risk in Europe. TBE surveillance is currently limited, in part, due to varying diagnostic guidelines, access to testing, and awareness of TBE. Consequently, TBE prevalence is underestimated and vaccination recommendations inadequate. TBE vaccine uptake is unsatisfactory in many TBE-endemic European countries. This review summarizes the findings of a scientific workshop of experts to improve TBE surveillance and vaccine uptake in Europe. Strategies to improve TBE surveillance and vaccine uptake should focus on: aligning diagnostic criteria and testing across Europe; expanding current vaccine recommendations and reducing their complexity; and increasing public education of the potential risks posed by TBEV infection.

1 June 2018 in Antiviral Research
Verified
Journal Article
Closed access
AIAleksandr Ianevski
Aleksandr Ianevski
EZEva Zusinaite
Eva Zusinaite
SKSuvi Kuivanen
Suvi Kuivanen
MSMårten Strand
Mårten Strand
HLHilde Lysvand
Hilde Lysvand
Denis KainovDenis Kainov
Denis Kainov

25 September 2017 in Viruses
Verified
Journal Article
Open access
PDF file
DBDaria Bulanova
Daria Bulanova
AIAleksandr Ianevski
Aleksandr Ianevski
ABAndrii Bugai
Andrii Bugai
YAYevhen Akimov
Yevhen Akimov
SKSuvi Kuivanen
Suvi Kuivanen
Denis KainovDenis Kainov
Denis Kainov
Viral diseases remain serious threats to public health because of the shortage of effective means of control. To combat the surge of viral diseases, new treatments are urgently needed. Here we show that small-molecules, which inhibit cellular anti-apoptotic Bcl-2 proteins (Bcl-2i), induced the premature death of cells infected with different RNA or DNA viruses, whereas, at the same concentrations, no toxicity was observed in mock-infected cells. Moreover, these compounds limited viral replication and spread. Surprisingly, Bcl-2i also induced the premature apoptosis of cells transfected with viral RNA or plasmid DNA but not of mock-transfected cells. These results suggest that Bcl-2i sensitizes cells containing foreign RNA or DNA to apoptosis. A comparison of the toxicity, antiviral activity, and side effects of six Bcl-2i allowed us to select A-1155463 as an antiviral lead candidate. Thus, our results pave the way for the further development of Bcl-2i for the prevention and treatment of viral diseases.